abstract: PURPOSE: To evaluate the potential benefit of 4   radiation therapy in recurrent, locally advanced, or metastatic @entity135 treated with stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: Twenty-seven @entity1 with 29 @entity5 who were treated using SBRT were included. In recurrent disease (n=26), SBRT was delivered with a median 44  Gy (range, 35-44  Gy) in 5 fractions. Three @entity1 with @entity320 , metastatic @entity0 , and primary @entity189 received 35  Gy, 22.5  Gy, and 40  Gy in 5 fractions, respectively. Novel 4   treatment plans were created for each @entity1 to meet the objective that 95% of the planning target volume was covered by 100% of the prescription dose. Doses to organs at risk (OARs) and 50% dose spillage volumes were compared against the delivered clinical SBRT plans. Local control (LC), late @entity137 , @entity5 ( @entity5 ), and normal tissue complication probability were determined. RESULTS: Using 4   plans, mean/maximum doses to all OARs were reduced by 22% to 89%/10% to 86%. With 4   plans, the 50% dose spillage volume was decreased by 33%. Planning target volume prescription dose escalation by 10  Gy and 20  Gy were achieved while keeping doses to OARs significantly improved or unchanged from clinical plans, except for the carotid artery maximum dose at 20-Gy escalation. At a median follow-up of 10  months (range, 1-41  months), crude LC was 52%. The 2-year LC of 39.2% approximated the predicted mean @entity5 of 42.2%, which increased to 45.9% with 4   plans. For 10-Gy and 20-Gy dose escalation, 4   plans increased @entity5 from 80.1% and 88.1% to 85.5% and 91.4%, respectively. The 7.4% rate of grade >= 3 late @entity137 was comparable to the predicted 5.6% mean normal tissue complication probability for OARs, which was significantly reduced by 4   planning at the prescribed and escalated doses. CONCLUSIONS: 4   plans may allow dose escalation with significant and consistent improvements in critical organ sparing, @entity5 control, and coverage.

title: 4   Noncoplanar Stereotactic Body Radiation Therapy for @entity135 : Potential to Improve Tumor Control and Late XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['head-and-neck cancer']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumor control probability', 'TCP', 'tumors']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['undifferentiated carcinoma']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['sinonasal mucosal melanoma']

answer: @entity137 :: (MESH:D064420,Disease) :: ['Toxicity']


abstract: PURPOSE: To evaluate the potential benefit of 4   radiation therapy in recurrent, locally advanced, or metastatic @entity135 treated with stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: Twenty-seven @entity1 with 29 @entity5 who were treated using SBRT were included. In recurrent disease (n=26), SBRT was delivered with a median 44  Gy (range, 35-44  Gy) in 5 fractions. Three @entity1 with @entity320 , metastatic @entity0 , and primary @entity189 received 35  Gy, 22.5  Gy, and 40  Gy in 5 fractions, respectively. Novel 4   treatment plans were created for each @entity1 to meet the objective that 95% of the planning target volume was covered by 100% of the prescription dose. Doses to organs at risk (OARs) and 50% dose spillage volumes were compared against the delivered clinical SBRT plans. Local control (LC), late @entity137 , @entity5 ( @entity5 ), and normal tissue complication probability were determined. RESULTS: Using 4   plans, mean/maximum doses to all OARs were reduced by 22% to 89%/10% to 86%. With 4   plans, the 50% dose spillage volume was decreased by 33%. Planning target volume prescription dose escalation by 10  Gy and 20  Gy were achieved while keeping doses to OARs significantly improved or unchanged from clinical plans, except for the carotid artery maximum dose at 20-Gy escalation. At a median follow-up of 10  months (range, 1-41  months), crude LC was 52%. The 2-year LC of 39.2% approximated the predicted mean @entity5 of 42.2%, which increased to 45.9% with 4   plans. For 10-Gy and 20-Gy dose escalation, 4   plans increased @entity5 from 80.1% and 88.1% to 85.5% and 91.4%, respectively. The 7.4% rate of grade >= 3 late @entity137 was comparable to the predicted 5.6% mean normal tissue complication probability for OARs, which was significantly reduced by 4   planning at the prescribed and escalated doses. CONCLUSIONS: 4   plans may allow dose escalation with significant and consistent improvements in critical organ sparing, @entity5 control, and coverage.

title: 4   Noncoplanar Stereotactic Body Radiation Therapy for XXXX : Potential to Improve Tumor Control and Late @entity137 .

answer: @entity135 :: (MESH:D006258,Disease) :: ['Head-and-Neck Cancer']


abstract: This multicentre open 6-week study evaluated the efficacy, safety and tolerability of @entity5470 , the first fully synthetic @entity2453 ( @entity2453 ) reductase inhibitor, in elderly @entity1 with type IIa hypercholesterolaemia. After a 4-week single-blind placebo period, 22 elderly @entity1 (mean age 68 +/- 5 years) with @entity298 [low density lipoprotein (LDL) @entity165 > 160 mg/dl] were enrolled in the trial. @entity5470 40 mg was administered once in the evening. At baseline, and after 3 and 6 weeks of treatment, total @entity165 , LDL @entity165 , high density lipoprotein (HDL) @entity165 , @entity1674 , apolipoproteins B ( @entity755 ) and A-I (apo A-I) were measured. Safety and tolerability were assessed by monitoring routine laboratory parameters and by recording spontaneously reported side effects. The mean (+/- SD) baseline total @entity165 , LDL @entity165 , @entity412 , HDL @entity165 , @entity755 and apo A-I levels were 325 +/- 43, 236 +/- 43, 128 +/- 56, 61 +/- 16, 221 +/- 60 and 164 +/- 28 mg/dl, respectively. After 6 weeks, @entity5470 significantly (p < 0.001, ANOVA test) reduced total @entity165 , LDL @entity165 and @entity755 levels by 22%, 29% and 23%, respectively. These significant reductions were already reached at week 3 (total @entity165 , -21%; LDL @entity165 , -27%). The total @entity165 : HDL @entity165 ratio was reduced by 22% at week 3 and by 21% at week 6 (from 5.3 to 4.2). 78% of the @entity1 showed a reduction > or = 20% for LDL @entity165 . @entity1674 were reduced by 16% (not significant).(ABSTRACT TRUNCATED AT 250 WORDS)

title: Efficacy and safety of @entity5470 , a new XXXX reductase inhibitor, in elderly hypercholesterolaemic @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity5470 :: ('MESH:C065180', 'Chemical') :: ['fluvastatin', 'Fluvastatin']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['Triglycerides', 'triglycerides']

entities_list: @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride']

entities_list: @entity2453 :: ('MESH:C008047', 'Chemical') :: ['3-hydroxy-3-methylglutaryl coenzyme A', 'HMG CoA']

entities_list: @entity298 :: ('MESH:D010538', 'Disease') :: ['primary hypercholesterolaemia']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity2453 :: (MESH:C008047,Chemical) :: ['HMG CoA']


abstract: This multicentre open 6-week study evaluated the efficacy, safety and tolerability of @entity5470 , the first fully synthetic @entity2453 ( @entity2453 ) reductase inhibitor, in elderly @entity1 with type IIa hypercholesterolaemia. After a 4-week single-blind placebo period, 22 elderly @entity1 (mean age 68 +/- 5 years) with @entity298 [low density lipoprotein (LDL) @entity165 > 160 mg/dl] were enrolled in the trial. @entity5470 40 mg was administered once in the evening. At baseline, and after 3 and 6 weeks of treatment, total @entity165 , LDL @entity165 , high density lipoprotein (HDL) @entity165 , @entity1674 , apolipoproteins B ( @entity755 ) and A-I (apo A-I) were measured. Safety and tolerability were assessed by monitoring routine laboratory parameters and by recording spontaneously reported side effects. The mean (+/- SD) baseline total @entity165 , LDL @entity165 , @entity412 , HDL @entity165 , @entity755 and apo A-I levels were 325 +/- 43, 236 +/- 43, 128 +/- 56, 61 +/- 16, 221 +/- 60 and 164 +/- 28 mg/dl, respectively. After 6 weeks, @entity5470 significantly (p < 0.001, ANOVA test) reduced total @entity165 , LDL @entity165 and @entity755 levels by 22%, 29% and 23%, respectively. These significant reductions were already reached at week 3 (total @entity165 , -21%; LDL @entity165 , -27%). The total @entity165 : HDL @entity165 ratio was reduced by 22% at week 3 and by 21% at week 6 (from 5.3 to 4.2). 78% of the @entity1 showed a reduction > or = 20% for LDL @entity165 . @entity1674 were reduced by 16% (not significant).(ABSTRACT TRUNCATED AT 250 WORDS)

title: Efficacy and safety of XXXX , a new @entity2453 reductase inhibitor, in elderly hypercholesterolaemic @entity1 .

answer: @entity5470 :: (MESH:C065180,Chemical) :: ['fluvastatin']


abstract: This multicentre open 6-week study evaluated the efficacy, safety and tolerability of @entity5470 , the first fully synthetic @entity2453 ( @entity2453 ) reductase inhibitor, in elderly @entity1 with type IIa hypercholesterolaemia. After a 4-week single-blind placebo period, 22 elderly @entity1 (mean age 68 +/- 5 years) with @entity298 [low density lipoprotein (LDL) @entity165 > 160 mg/dl] were enrolled in the trial. @entity5470 40 mg was administered once in the evening. At baseline, and after 3 and 6 weeks of treatment, total @entity165 , LDL @entity165 , high density lipoprotein (HDL) @entity165 , @entity1674 , apolipoproteins B ( @entity755 ) and A-I (apo A-I) were measured. Safety and tolerability were assessed by monitoring routine laboratory parameters and by recording spontaneously reported side effects. The mean (+/- SD) baseline total @entity165 , LDL @entity165 , @entity412 , HDL @entity165 , @entity755 and apo A-I levels were 325 +/- 43, 236 +/- 43, 128 +/- 56, 61 +/- 16, 221 +/- 60 and 164 +/- 28 mg/dl, respectively. After 6 weeks, @entity5470 significantly (p < 0.001, ANOVA test) reduced total @entity165 , LDL @entity165 and @entity755 levels by 22%, 29% and 23%, respectively. These significant reductions were already reached at week 3 (total @entity165 , -21%; LDL @entity165 , -27%). The total @entity165 : HDL @entity165 ratio was reduced by 22% at week 3 and by 21% at week 6 (from 5.3 to 4.2). 78% of the @entity1 showed a reduction > or = 20% for LDL @entity165 . @entity1674 were reduced by 16% (not significant).(ABSTRACT TRUNCATED AT 250 WORDS)

title: Efficacy and safety of @entity5470 , a new @entity2453 reductase inhibitor, in elderly hypercholesterolaemic XXXX .

answer: @entity1 :: (9606,Species) :: ['women']


abstract: We assessed the left ventricular (LV) contractile reserve in young adults with repaired @entity1498 and interrupted aortic arch by determination of LV force-frequency relation (FFR). Eighteen (7 @entity1 ) @entity1 aged 24.2    5.4  years and 20 (9 @entity1 ) healthy controls were studied. Blood pressures in the right arm were measured by oscillometry. Transmitral early (E) and late (A) diastolic velocities, tissue Doppler-derived mitral annular systolic (sm), early diastolic (em) and late diastolic (am) velocities, and myocardial @entity11139 ( @entity11139 ) were measured. The LV FFR and average slope were derived from the @entity11139 measured at different heart rates during supine bicycle exercise. Blood pressures at rest were similar between @entity1 and controls (all p >0.05). At baseline, @entity1 compared with controls had significantly greater E velocity, E/A and E/em ratios, and lower sm and em velocities (all p <0.05) but similar @entity11139 (p  = 0.18). At submaximal exercise, diastolic (p  = 0.001) and mean (p  = 0.003) blood pressures became significantly higher in @entity1 than controls, sm (p  = 0.001) and em (p <0.001) velocities remained reduced, whereas the @entity11139 became lower (p <0.001). The weighted average FFR was flattened (p <0.001), and average FFR slope was lower (p <0.001) in @entity1 compared with controls. The average FFR slope correlated negatively with the magnitude of exercise-induced increase in systolic (r  =  -0.32, p  = 0.050), mean (r  =  -0.41, p  = 0.011), and diastolic (r  =  -0.40, p  = 0.013) blood pressures. In conclusion, young adults after @entity1498 and interrupted aortic arch repair exhibit reduced LV contractile reserve, which is related to the blood pressure response during exercise stress.

title: Left Ventricular Contractile Reserve in Young Adults Long-Term After Repair of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'men']

entities_list: @entity1498 :: ('MESH:D001017', 'Disease') :: ['coarctation of the aorta']

entities_list: @entity11139 :: ('MESH:D015465', 'Disease') :: ['isovolumic acceleration', 'IVA']

answer: @entity1498 :: (MESH:D001017,Disease) :: ['Coarctation of the Aorta']


abstract: Effects of @entity1827 ( @entity1827 ) and @entity1826 ( @entity1826 ) on @entity1919 ( @entity268 ) levels were studied in the isolated @entity35 anterior and intermediate-posterior pituitary slices. In the anterior pituitary, @entity1827 increased @entity268 levels in a concentration-dependent manner (10(-7)-10(-5) M). @entity1826 also increased the levels at the same concentration range, but @entity1827 was more potent than @entity1826 at an approximate ED50, 10(-6) M. The stimulatory effects of @entity20929 (10(-6) M) on @entity268 levels were antagonized by the @entity11081 receptor antagonist @entity11344 , 2 x 10(-6) M, and the ETB receptor agonist @entity13071 evoked only a weak increase in @entity268 levels. Moreover, the effects of @entity20929 were completely abolished by the cyclooxygenase inhibitor @entity3352 , 2 x 10(-5) M. On the other hand, among @entity2918 , @entity1421 ( @entity1421 ) increased @entity268 levels in a concentration-dependent manner (10(-7)-10(-5) M), whereas @entity1672 and @entity4770 did not exhibit such effects. @entity1421 levels were increased by application of @entity1827 (10(-8)-10(-5) M). The @entity1827 -induced @entity1421 accumulation was strongly inhibited by @entity3352 and @entity11344 , but not by treatment with pertussis toxin (100 ng/ml, 6 hr). Treatment with the phosphodiesterase inhibitor @entity1922 also elevated the @entity268 level by approximately 9-fold above the basal @entity268 level. After @entity1922 , @entity1827 failed to increase @entity1421 and @entity268 levels. In the intermediate-posterior pituitary, @entity20929 did not affect @entity268 levels. The results suggest that endothelins increase @entity268 levels via @entity11081 receptor activation interacting with the pertussis toxin-insensitive G-protein, in which @entity1421 production is involved in the @entity35 anterior pituitary, whereas endothelins lack these effects in the intermediate-posterior pituitary.

title: Endothelins stimulate XXXX accumulation in the isolated @entity35 anterior pituitary gland: possible involvement of @entity11081 receptor activation and @entity1421 production.

entities_list: @entity1672 :: ('MESH:D015230', 'Chemical') :: ['prostaglandin D2']

entities_list: @entity1421 :: ('MESH:D015232', 'Chemical') :: ['PGE2', 'prostaglandin E2']

entities_list: @entity2918 :: ('MESH:D011453', 'Chemical') :: ['prostaglandins']

entities_list: @entity1922 :: ('MESH:D015056', 'Chemical') :: ['3-isobutyl-1-methylxanthine']

entities_list: @entity4770 :: ('MESH:D011464', 'Chemical') :: ['prostaglandin I2']

entities_list: @entity1919 :: ('MESH:D000242', 'Chemical') :: ['cyclic AMP']

entities_list: @entity3352 :: ('MESH:D007213', 'Chemical') :: ['indomethacin']

answer: @entity1919 :: (MESH:D000242,Chemical) :: ['cyclic AMP']


abstract: Effects of @entity1827 ( @entity1827 ) and @entity1826 ( @entity1826 ) on @entity1919 ( @entity268 ) levels were studied in the isolated @entity35 anterior and intermediate-posterior pituitary slices. In the anterior pituitary, @entity1827 increased @entity268 levels in a concentration-dependent manner (10(-7)-10(-5) M). @entity1826 also increased the levels at the same concentration range, but @entity1827 was more potent than @entity1826 at an approximate ED50, 10(-6) M. The stimulatory effects of @entity20929 (10(-6) M) on @entity268 levels were antagonized by the @entity11081 receptor antagonist @entity11344 , 2 x 10(-6) M, and the ETB receptor agonist @entity13071 evoked only a weak increase in @entity268 levels. Moreover, the effects of @entity20929 were completely abolished by the cyclooxygenase inhibitor @entity3352 , 2 x 10(-5) M. On the other hand, among @entity2918 , @entity1421 ( @entity1421 ) increased @entity268 levels in a concentration-dependent manner (10(-7)-10(-5) M), whereas @entity1672 and @entity4770 did not exhibit such effects. @entity1421 levels were increased by application of @entity1827 (10(-8)-10(-5) M). The @entity1827 -induced @entity1421 accumulation was strongly inhibited by @entity3352 and @entity11344 , but not by treatment with pertussis toxin (100 ng/ml, 6 hr). Treatment with the phosphodiesterase inhibitor @entity1922 also elevated the @entity268 level by approximately 9-fold above the basal @entity268 level. After @entity1922 , @entity1827 failed to increase @entity1421 and @entity268 levels. In the intermediate-posterior pituitary, @entity20929 did not affect @entity268 levels. The results suggest that endothelins increase @entity268 levels via @entity11081 receptor activation interacting with the pertussis toxin-insensitive G-protein, in which @entity1421 production is involved in the @entity35 anterior pituitary, whereas endothelins lack these effects in the intermediate-posterior pituitary.

title: Endothelins stimulate @entity1919 accumulation in the isolated @entity35 anterior pituitary gland: possible involvement of @entity11081 receptor activation and XXXX production.

answer: @entity1421 :: (MESH:D015232,Chemical) :: ['prostaglandin E2']


abstract: Effects of @entity1827 ( @entity1827 ) and @entity1826 ( @entity1826 ) on @entity1919 ( @entity268 ) levels were studied in the isolated @entity35 anterior and intermediate-posterior pituitary slices. In the anterior pituitary, @entity1827 increased @entity268 levels in a concentration-dependent manner (10(-7)-10(-5) M). @entity1826 also increased the levels at the same concentration range, but @entity1827 was more potent than @entity1826 at an approximate ED50, 10(-6) M. The stimulatory effects of @entity20929 (10(-6) M) on @entity268 levels were antagonized by the @entity11081 receptor antagonist @entity11344 , 2 x 10(-6) M, and the ETB receptor agonist @entity13071 evoked only a weak increase in @entity268 levels. Moreover, the effects of @entity20929 were completely abolished by the cyclooxygenase inhibitor @entity3352 , 2 x 10(-5) M. On the other hand, among @entity2918 , @entity1421 ( @entity1421 ) increased @entity268 levels in a concentration-dependent manner (10(-7)-10(-5) M), whereas @entity1672 and @entity4770 did not exhibit such effects. @entity1421 levels were increased by application of @entity1827 (10(-8)-10(-5) M). The @entity1827 -induced @entity1421 accumulation was strongly inhibited by @entity3352 and @entity11344 , but not by treatment with pertussis toxin (100 ng/ml, 6 hr). Treatment with the phosphodiesterase inhibitor @entity1922 also elevated the @entity268 level by approximately 9-fold above the basal @entity268 level. After @entity1922 , @entity1827 failed to increase @entity1421 and @entity268 levels. In the intermediate-posterior pituitary, @entity20929 did not affect @entity268 levels. The results suggest that endothelins increase @entity268 levels via @entity11081 receptor activation interacting with the pertussis toxin-insensitive G-protein, in which @entity1421 production is involved in the @entity35 anterior pituitary, whereas endothelins lack these effects in the intermediate-posterior pituitary.

title: Endothelins stimulate @entity1919 accumulation in the isolated @entity35 anterior pituitary gland: possible involvement of XXXX receptor activation and @entity1421 production.

answer: @entity11081 :: (24326(Tax:10116),Gene) :: ['ETA']


abstract: Effects of @entity1827 ( @entity1827 ) and @entity1826 ( @entity1826 ) on @entity1919 ( @entity268 ) levels were studied in the isolated @entity35 anterior and intermediate-posterior pituitary slices. In the anterior pituitary, @entity1827 increased @entity268 levels in a concentration-dependent manner (10(-7)-10(-5) M). @entity1826 also increased the levels at the same concentration range, but @entity1827 was more potent than @entity1826 at an approximate ED50, 10(-6) M. The stimulatory effects of @entity20929 (10(-6) M) on @entity268 levels were antagonized by the @entity11081 receptor antagonist @entity11344 , 2 x 10(-6) M, and the ETB receptor agonist @entity13071 evoked only a weak increase in @entity268 levels. Moreover, the effects of @entity20929 were completely abolished by the cyclooxygenase inhibitor @entity3352 , 2 x 10(-5) M. On the other hand, among @entity2918 , @entity1421 ( @entity1421 ) increased @entity268 levels in a concentration-dependent manner (10(-7)-10(-5) M), whereas @entity1672 and @entity4770 did not exhibit such effects. @entity1421 levels were increased by application of @entity1827 (10(-8)-10(-5) M). The @entity1827 -induced @entity1421 accumulation was strongly inhibited by @entity3352 and @entity11344 , but not by treatment with pertussis toxin (100 ng/ml, 6 hr). Treatment with the phosphodiesterase inhibitor @entity1922 also elevated the @entity268 level by approximately 9-fold above the basal @entity268 level. After @entity1922 , @entity1827 failed to increase @entity1421 and @entity268 levels. In the intermediate-posterior pituitary, @entity20929 did not affect @entity268 levels. The results suggest that endothelins increase @entity268 levels via @entity11081 receptor activation interacting with the pertussis toxin-insensitive G-protein, in which @entity1421 production is involved in the @entity35 anterior pituitary, whereas endothelins lack these effects in the intermediate-posterior pituitary.

title: Endothelins stimulate @entity1919 accumulation in the isolated XXXX anterior pituitary gland: possible involvement of @entity11081 receptor activation and @entity1421 production.

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: Bath @entity1691 Activity Index (BASDAI) is the most frequently used @entity1691 activity assesment by which through 6 questions 5 basic diseases symptoms ( @entity1295 , @entity615 , @entity158 /swelling, enthesitic points, intensity and duration of @entity7127 ) are being evaluated. In distinction from mentioned, @entity1691 Activity Score (ASDAS) is the first validated index for the @entity5427 activity assessment with the @entity1 's assessments of the disease symptoms ( @entity615 , duration of the morning stiffess, activity of the disease, @entity158 ) includes the acute phase reactants (SE or CRP). We compared BASDAI and ASDAS indexes to the group of @entity1 with the @entity5427 , in order to evaluate their congruence and to evaluate the inluence of @entity615 at obtained values. The cross-sectional study was performed in a group of 36 @entity1 with the @entity5427 whose disease activity levels were evaluated by the BASDAI and ASDAS (SE) index. Statistical data analysis was performed by Student t-test and frequency tables for non-parameter data. As it has been expected the significant correlation between BASDAI and ASDAS indexes has been confirmed (r=0.796; p=0.00). BASDAI/ASDAS average value of all of the @entity1 was 4.2/2.8. From 36 @entity1 with the @entity5427 according to the BASDAI index 42% had mild active disease (BASDAI <4), while according to ASDAS index 44% @entity1 had very active disease (ASDAS 2.1-.5.3). Higher activity of the disease according to ASDAS index is the result of the elevated sedimentation which is assessed only in ASDAS index. @entity1 with higher BASDAI index statistically have more significantly expressed @entity1295 and @entity158 without statistically significant difference in sedimentation (p=0.120). Examinees with higher ASDAS index have also significantly more expressed @entity615 , but unlike BASDAI they have sedimentation (p=0.001). ASDAS is more recent clinical indicator of the @entity5427 activities which could be compared to BASDAI instrument. In this group of @entity1 ASDAS seems to be more sensitive index because it discriminates more @entity1 with the active disease.

title: [Scoring of disease activity using BASDAI and ASDAS method in XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity615 :: ('MESH:D001416', 'Disease') :: ['fatigue and back pain', 'back pain', 'SE, fatigue and back pain']

entities_list: @entity1691 :: ('MESH:D013167', 'Disease') :: ['Ankylosing Spondylitis Disease', 'ankylosing spondylitis']

entities_list: @entity7127 :: ('MESH:D048968', 'Disease') :: ['morning stiffness']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['joint pain', 'spinal pain', 'pains and swelling of the peripheral joints']

answer: @entity1691 :: (MESH:D013167,Disease) :: ['ankylosing spondylitis']


abstract: The classification of @entity535 residues based on the events of contact formation between distinct @entity535 and selected @entity2036 was constructed. Thus, the most integral properties, that characterize interactions in organization of DNA-protein complexes, were used. We applied the Voronoi-Delaunay tessellation to draw statistics of contacts and area of contacts for the set included 1937 DNA-protein complexes. Similarities of @entity535 residues have been searched for based on the comparison of corresponded rows and matrixes of contacts and areas of contacts. Nine measures of distance were used for estimation of rows similarity degree. The procedure of clustering @entity1522 in groups included three hierarchical and two nonhierarchical methods. A total tree was built using nine techniques of estimating distance with three hierarchical clustering methods. It was shown that clustering centers in the main groups are always constant while other relationships between objects vary. Clustering of binary associations was found for the most @entity1522 . Major classes of up to six @entity1522 correspond to the certain local structures of the polypeptide chain in the context of @entity535 composition. These data should be taken into account when designing DNA-protein ligands.

title: [Classification of XXXX based on a comparative analysis of contacts in DNA-protein complexes and specific DNA-protein interactions].

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

entities_list: @entity1522 :: ('CHEBI:33709', 'Chemical') :: ['amino acids']

entities_list: @entity2036 :: ('MESH:D009711', 'Chemical') :: ['nucleotides']

answer: @entity1522 :: (CHEBI:33709,Chemical) :: ['amino acids']


abstract: @entity461 ( @entity461 ) is @entity551 in mammals and is a potent coronary vasodilator. @entity4293 ( @entity4293 ) has been reported to have similar vascular activity. In the present study, the effects of @entity1 @entity461 ( @entity461 ) and @entity1 @entity4293 (hPTHrp) were compared in various in vivo and in vitro assays. In vivo studies included blood pressure measurement and coronary blood flow determination with labeled microspheres in anesthetized and cannulated normotensive @entity35 . Isolated @entity35 tail artery and portal vein helical strips were used in studying tension development in vitro. In the blood pressure assay, @entity4293 was several times more potent than @entity461 . @entity4293 was also significantly more potent than @entity461 in relaxing tail artery precontracted with @entity5463 ( @entity1831 ). @entity4293 and @entity461 both inhibited the spontaneously contracting portal vein, but again @entity4293 was significantly more potent. @entity4293 (1 microgram/kg) produced a greater increase in coronary blood flow as compared with the same dose of @entity461 . These data suggest that @entity4293 is more potent than @entity461 in its cardiovascular actions. It is possible that @entity4293 is the endogenous vasodilating ligand, and the structural similarity between @entity461 and @entity4293 may explain the pharmacological action of @entity461 . It is therefore unlikely that @entity461 or @entity4293 may be involved in the genesis or maintenance of @entity101 . Because the parathyroid gland seems to be involved in some forms of essential @entity101 , factor(s) other than @entity461 or @entity4293 may be responsible.

title: Cardiovascular effects of @entity1 @entity461 and XXXX -related peptide.

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity4293 :: ('5744', 'Gene') :: ['PTHrp', 'Parathyroid hormone-related peptide']

entities_list: @entity5463 :: ('MESH:D001127', 'Chemical') :: ['arginine vasopressin']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotensive']

entities_list: @entity461 :: ('5741', 'Gene') :: ['hPTH', 'PTH', 'Parathyroid hormone']

answer: @entity461 :: (5741,Gene) :: ['parathyroid hormone']


abstract: @entity461 ( @entity461 ) is @entity551 in mammals and is a potent coronary vasodilator. @entity4293 ( @entity4293 ) has been reported to have similar vascular activity. In the present study, the effects of @entity1 @entity461 ( @entity461 ) and @entity1 @entity4293 (hPTHrp) were compared in various in vivo and in vitro assays. In vivo studies included blood pressure measurement and coronary blood flow determination with labeled microspheres in anesthetized and cannulated normotensive @entity35 . Isolated @entity35 tail artery and portal vein helical strips were used in studying tension development in vitro. In the blood pressure assay, @entity4293 was several times more potent than @entity461 . @entity4293 was also significantly more potent than @entity461 in relaxing tail artery precontracted with @entity5463 ( @entity1831 ). @entity4293 and @entity461 both inhibited the spontaneously contracting portal vein, but again @entity4293 was significantly more potent. @entity4293 (1 microgram/kg) produced a greater increase in coronary blood flow as compared with the same dose of @entity461 . These data suggest that @entity4293 is more potent than @entity461 in its cardiovascular actions. It is possible that @entity4293 is the endogenous vasodilating ligand, and the structural similarity between @entity461 and @entity4293 may explain the pharmacological action of @entity461 . It is therefore unlikely that @entity461 or @entity4293 may be involved in the genesis or maintenance of @entity101 . Because the parathyroid gland seems to be involved in some forms of essential @entity101 , factor(s) other than @entity461 or @entity4293 may be responsible.

title: Cardiovascular effects of @entity1 XXXX and @entity461 -related peptide.

answer: @entity461 :: (5741,Gene) :: ['parathyroid hormone']


abstract: @entity461 ( @entity461 ) is @entity551 in mammals and is a potent coronary vasodilator. @entity4293 ( @entity4293 ) has been reported to have similar vascular activity. In the present study, the effects of @entity1 @entity461 ( @entity461 ) and @entity1 @entity4293 (hPTHrp) were compared in various in vivo and in vitro assays. In vivo studies included blood pressure measurement and coronary blood flow determination with labeled microspheres in anesthetized and cannulated normotensive @entity35 . Isolated @entity35 tail artery and portal vein helical strips were used in studying tension development in vitro. In the blood pressure assay, @entity4293 was several times more potent than @entity461 . @entity4293 was also significantly more potent than @entity461 in relaxing tail artery precontracted with @entity5463 ( @entity1831 ). @entity4293 and @entity461 both inhibited the spontaneously contracting portal vein, but again @entity4293 was significantly more potent. @entity4293 (1 microgram/kg) produced a greater increase in coronary blood flow as compared with the same dose of @entity461 . These data suggest that @entity4293 is more potent than @entity461 in its cardiovascular actions. It is possible that @entity4293 is the endogenous vasodilating ligand, and the structural similarity between @entity461 and @entity4293 may explain the pharmacological action of @entity461 . It is therefore unlikely that @entity461 or @entity4293 may be involved in the genesis or maintenance of @entity101 . Because the parathyroid gland seems to be involved in some forms of essential @entity101 , factor(s) other than @entity461 or @entity4293 may be responsible.

title: Cardiovascular effects of XXXX @entity461 and @entity461 -related peptide.

answer: @entity1 :: (9606,Species) :: ['human']


abstract: UNASSIGNED: Quantification by mass spectrometry imaging (Q- @entity17798 ) is one of the hottest topics of the current discussions among the experts of the @entity15 imaging community. If @entity17798 is established as a powerful qualitative tool in drug and biomarker discovery, its reliability for absolute and accurate quantification (QUAN) is still controversial. Indeed, Q- @entity17798 has to deal with several fundamental aspects that are difficult to control, and to account for absolute quantification. The first objective of this manuscript is to review the state-of-the-art of  Q- @entity17798 and the current strategies developed for absolute quantification by direct surface sampling from tissue sections. This includes comments on the quest for the perfect matrix-matched standards and signal normalization approaches. Furthermore, this work investigates quantification at a pixel level to determine how many pixels must be considered for accurate quantification by ultraviolet matrix-assisted laser desorption/ionization (MALDI), the most widely used technique for @entity17798 . Particularly, this study focuses on the MALDI-selected reaction monitoring (SRM) in rastering mode, previously demonstrated as a quantitative and robust approach for small analyte and peptide-targeted analyses. The importance of designing experiments of good quality and the use of a labeled compound for signal normalization is emphasized to minimize the signal variability. This is exemplified by measuring the signal for cocaine and a tryptic peptide (i.e., obtained after digestion of a monoclonal antibody) upon different experimental conditions, such as sample stage velocity, laser power and frequency, or distance between two raster lines. Our findings show that accurate quantification cannot be performed on a single pixel but requires averaging of at least 4-5  pixels. The present work demonstrates that MALDI-SRM/ @entity17798 is quantitative with precision better than 10-15  %, which meets the requirements of most guidelines (i.e., in bioanalysis or toxicology) for quantification of drugs or peptides from tissue homogenates.

title: Quantification in MALDI- XXXX imaging: what can we learn from MALDI-selected reaction monitoring and what can we expect for imaging?

answer: @entity15 :: (MESH:D009103,Disease) :: ['MS']


abstract: Several chromosomal rearrangements involving band 3q26 are known to induce @entity22213 overexpression. They include inv(3)(q21q26), t(3;3)(q21;q26), t(3;21)(q26;q22) and t(3;12)(q26;p13). Translocations involving the short arm of chromosome 2 and 3q26 have been reported in more than 50 @entity1 with @entity74 . However, although the breakpoints on 2p are scattered over a long segment, their distribution had only been analyzed in 9 @entity1 . We performed fluorescent in situ hybridization with a library of BAC (Bacterial Artificial Chromosome) clones in 4 @entity1 with t(2;3)(p15-23;q26). Our results combined with those of the 9 previously reported @entity1 showed scattering of the breakpoints in 2 regions. A 1.08Mb region in band 2p21 encompassing the @entity60496 , @entity58758 and @entity43258 genes was documented in 5 @entity1 . A second region of 1.83Mb in band 2p16.1 was identified in 8 @entity1 . Four @entity1 showed clustering around the @entity21270 gene and the remaining 4 around a long intergenic non-coding RNA, FLJ30838. These regions are characterized by the presence of regulatory sequences (CpG islands and promoters) that could be instrumental in @entity22213 overexpression.

title: Breakpoint heterogeneity in (2;3)(p15-23;q26) translocations involving XXXX in myeloid hemopathies.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['myeloid disorders']

answer: @entity22213 :: (2122,Gene) :: ['EVI1']


abstract: In @entity4098 , the epidermis contains large clear neoplastic cells. To explain the pathogenesis of this disease, the immunohistochemical characteristics of these cells were investigated in 25 @entity1 . The cytoplasmic presence of low molecular weight cytokeratin and the absence of high molecular weight cytokeratin in all cases confirmed the glandular origin of the Paget cells. Membrane over-expression of the @entity52120 -protein was established in 96% of cases. It was hypothesized that epidermal keratinocytes release a chemotactic factor which attracts @entity52120 -over-expressing @entity0 cells by @entity6722 into the epidermis. The biological assays showed that normal keratinocytes release one or more chemotactic factor(s) into their conditioned medium, which induced spreading and motility of @entity52120 -over-expressing SK-BR-3 @entity1 @entity0 cells. The conditioned medium of keratinocytes also attracted the SK-BR-3 cells by @entity6722 in a modified Boyden chamber. Furthermore, MCF-7 @entity1 @entity0 cells, which do not over-express the @entity52120 -protein, were not attracted by @entity6722 of conditioned medium of @entity1 keratinocytes. The involvement of the @entity52120 -protein in spreading, motility and @entity6722 is further indicated by the inhibition of these processes by monoclonal antibodies against the extracellular domain of the @entity52120 -protein. We conclude, therefore, that the Paget cells spread through the epidermis due to the motility induced by a chemotactic factor, which is released by epidermal keratinocytes and whose influence is mediated by the @entity52120 -protein.

title: Keratinocyte induced XXXX in the pathogenesis of @entity4098 .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity6722 :: ('MESH:C565534', 'Disease') :: ['chemotaxis']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast carcinoma', 'breast cancer']

entities_list: @entity4098 :: ('MESH:D010144', 'Disease') :: ["Paget's disease of the breast"]

answer: @entity6722 :: (MESH:C565534,Disease) :: ['chemotaxis']


abstract: In @entity4098 , the epidermis contains large clear neoplastic cells. To explain the pathogenesis of this disease, the immunohistochemical characteristics of these cells were investigated in 25 @entity1 . The cytoplasmic presence of low molecular weight cytokeratin and the absence of high molecular weight cytokeratin in all cases confirmed the glandular origin of the Paget cells. Membrane over-expression of the @entity52120 -protein was established in 96% of cases. It was hypothesized that epidermal keratinocytes release a chemotactic factor which attracts @entity52120 -over-expressing @entity0 cells by @entity6722 into the epidermis. The biological assays showed that normal keratinocytes release one or more chemotactic factor(s) into their conditioned medium, which induced spreading and motility of @entity52120 -over-expressing SK-BR-3 @entity1 @entity0 cells. The conditioned medium of keratinocytes also attracted the SK-BR-3 cells by @entity6722 in a modified Boyden chamber. Furthermore, MCF-7 @entity1 @entity0 cells, which do not over-express the @entity52120 -protein, were not attracted by @entity6722 of conditioned medium of @entity1 keratinocytes. The involvement of the @entity52120 -protein in spreading, motility and @entity6722 is further indicated by the inhibition of these processes by monoclonal antibodies against the extracellular domain of the @entity52120 -protein. We conclude, therefore, that the Paget cells spread through the epidermis due to the motility induced by a chemotactic factor, which is released by epidermal keratinocytes and whose influence is mediated by the @entity52120 -protein.

title: Keratinocyte induced @entity6722 in the pathogenesis of XXXX .

answer: @entity4098 :: (MESH:D010144,Disease) :: ['Paget's disease of the breast']


abstract: BACKGROUND: @entity4512 at several sites (multisite @entity158 ) is more common than single-site @entity158 . Little is known on its effects on @entity717 ( @entity717 ) retirement. METHODS: A nationally representative sample comprised 4071 Finns in the workforce aged 30 to 63. Data (questionnaire, interview, clinical examination) were gathered in 2000-2001 and linked with national @entity717 registers for 2000-2011. @entity158 during the preceding month in 18 locations was combined into four sites (neck, upper limbs, low back, lower limbs). Hazard ratios (HR) of @entity717 were estimated by Cox regression. RESULTS: The HR of any @entity717 (n   =   477) was 1.6 (95% confidence interval 1.2-2.1) for one, 2.5 (1.9-3.3) for two, 3.1 (2.3-4.3) for three and 5.6 (4.0-7.8) for four @entity158 sites, when adjusted for age and gender. When additionally adjusted for clinically assessed @entity102 , the HRs varied from 1.4 (1.0-1.8) to 3.5 (2.5-4.9), respectively. When further adjusted for physical and psychosocial workload, education, body mass index, smoking, exercise and @entity25 , the HRs were 1.3 (0.9-1.7), 1.6 (1.2-2.2), 1.8 (1.3-2.5) and 2.5 (1.8-3.6). The number of @entity158 sites was especially strong in predicting DPs due to @entity85 (HRs in the full model; 3.1 to 4.3), but it also predicted DPs due to other @entity66 (respective HRs 1.3 to 2.3); @entity158 in all four sites was also predictive of DPs due to @entity146 (full model HR 2.2). CONCLUSIONS: The number of @entity158 sites independently predicted @entity717 retirement. Employees with multisite @entity158 may need specific support to maintain their work ability.

title: Multisite XXXX predicts medically certified disability retirement among Finns.

entities_list: @entity4512 :: ('MESH:D059352', 'Disease') :: ['Musculoskeletal pain']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['somatic diseases']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['mental disorders']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic diseases']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['disability pension', 'DP']

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['musculoskeletal diseases']

entities_list: @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep disorders']

answer: @entity4512 :: (MESH:D059352,Disease) :: ['musculoskeletal pain']


abstract: BACKGROUND/PURPOSE: The purpose of this study was to investigate effects of risk factors on recurrence of @entity44 ( @entity44 ). METHODS: A retrospective review was conducted of 107 SCTs treated between January 2003 and December 2012 in our center. Risk factors were identified by univariate and multivariate analysis. RESULTS: Sixteen @entity1 had recurrence of @entity44 a median interval of 16.25months after primary surgery. 15.6% @entity5 recurrence were Altman type I, 10.5% type II, 10.0% type III, and 31.3% type IV. The recurrence of mature @entity44 was observed in 8 @entity1 , immature in 2, malignant in 5. More than half of the recurrences showed a shift towards histological immaturity or @entity5 , compared with the @entity5 pathology. Risk factors for recurrence were spillage of @entity5 parenchyma during operation (P=0.028), incomplete resection (p=0.000), and primary immature (P=0.029) and malignant histology (P=0.026). Size, Altman classification, and age were not risk factors for recurrence. There was a statistically significant difference in OS between @entity1 who developed relapse (64.8%) and those who did not (95.0%) (P=0.0002). CONCLUSIONS: @entity5 recurrence affected the outcome of @entity1 with @entity44 . Risk factors were @entity5 spillage, immature and malignant histology, or incomplete resection. Regular follow-up after surgery is mandatory to find @entity5 relapse earlier and to improve the outcome.

title: Analysis of recurrence risks for XXXX in @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor', 'primary tumor', 'malignancy', 'tumors']

entities_list: @entity44 :: ('MESH:D013724', 'Disease') :: ['teratoma', 'sacrococcygeal teratoma', 'SCT']

answer: @entity44 :: (MESH:D013724,Disease) :: ['sacrococcygeal teratoma']


abstract: BACKGROUND/PURPOSE: The purpose of this study was to investigate effects of risk factors on recurrence of @entity44 ( @entity44 ). METHODS: A retrospective review was conducted of 107 SCTs treated between January 2003 and December 2012 in our center. Risk factors were identified by univariate and multivariate analysis. RESULTS: Sixteen @entity1 had recurrence of @entity44 a median interval of 16.25months after primary surgery. 15.6% @entity5 recurrence were Altman type I, 10.5% type II, 10.0% type III, and 31.3% type IV. The recurrence of mature @entity44 was observed in 8 @entity1 , immature in 2, malignant in 5. More than half of the recurrences showed a shift towards histological immaturity or @entity5 , compared with the @entity5 pathology. Risk factors for recurrence were spillage of @entity5 parenchyma during operation (P=0.028), incomplete resection (p=0.000), and primary immature (P=0.029) and malignant histology (P=0.026). Size, Altman classification, and age were not risk factors for recurrence. There was a statistically significant difference in OS between @entity1 who developed relapse (64.8%) and those who did not (95.0%) (P=0.0002). CONCLUSIONS: @entity5 recurrence affected the outcome of @entity1 with @entity44 . Risk factors were @entity5 spillage, immature and malignant histology, or incomplete resection. Regular follow-up after surgery is mandatory to find @entity5 relapse earlier and to improve the outcome.

title: Analysis of recurrence risks for @entity44 in XXXX .

answer: @entity1 :: (9606,Species) :: ['children']


abstract: @entity1 with the @entity10409 Syndrome (POTS) have orthostatic intolerance, as well as exercise intolerance. Peak @entity26 uptake (VO2peak) is generally lower in these @entity1 compared with healthy sedentary individuals, suggesting a lower physical fitness level. During acute exercise, POTS @entity1 have an excessive increase in heart rate and reduced @entity64 volume for each level of absolute workload; however, when expressed at relative workload (%VO2peak), there is no difference in the heart rate response between @entity1 and healthy individuals. The relationship between cardiac output and VO2 is similar between POTS @entity1 and healthy individuals. Short-term (i.e., 3months) exercise training increases cardiac size and mass, blood volume, and VO2peak in POTS @entity1 . Exercise performance is improved after training. Specifically, @entity64 volume is greater and heart rate is lower at any given VO2 during exercise after training versus before training. Peak heart rate is the same but peak @entity64 volume and cardiac output are greater after training. Heart rate recovery from peak exercise is significantly faster after training, indicating an improvement in autonomic circulatory control. These results suggest that @entity1 with POTS have no intrinsic abnormality of heart rate regulation during exercise. The @entity591 in POTS is due to a reduced @entity64 volume. Cardiac remodeling and blood volume expansion associated with exercise training increase physical fitness and improve exercise performance in these @entity1 .

title: Exercise in the postural XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity10409 :: ('MESH:D054972', 'Disease') :: ['Postural Orthostatic Tachycardia']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity591 :: ('MESH:D013610', 'Disease') :: ['tachycardia']

answer: @entity591 :: (MESH:D013610,Disease) :: ['orthostatic tachycardia syndrome']


abstract: This study presents the results of the response of Sparus aurata to three different musical stimuli, derived from the transmission (4  h per day, 5  days per week) of particular music pieces by Mozart, Romanza and @entity25781 (140  dBrms re 1   Pa), compared to the same transmission level of white noise, while the underwater ambient noise in all the experimental tanks was 121  dBrms re 1   Pa. Using recirculating sea water facilities, 10 groups, 2 for each treatment, of 20 specimens of 11.2      0.02  g (S.E.), were reared for 94  days, under 150      10  l* 12L-12D, and were fed an artificial diet three times per day. Fish body weight showed significant differences after 55  days, while its maximum level was observed after the 69th day until the end of the experiment, the highest value demonstrated in Mozart (M) groups, followed by those of Romanza (R), @entity25781 (B), control (C) and white noise (WN). SGR (M  =  B), %WG (M  =  B) and FCR (all groups fed same % b.w.) were also improved for M group. Brain neurotransmitters results exhibited significant differences in DA- @entity935 , (M  >  B), @entity5581 (C  >  B), 5HIAA:5HT (WN  >  R), @entity4925 (M  >  B), @entity4925 :DA and ( @entity4925  +  @entity3829 ):DA, (C  >  M), while no significant differences were observed in 5HT, NA, @entity3829 and @entity3829 :DA. No differences were observed in biometric measurements, protease activity, % @entity1718 of fillet, visceral fat and liver, while differences were observed regarding carbohydrase activity and the amount (mg/g w.w.) of some @entity1718 in liver, fillet and visceral fat. In conclusion, present results confirm those reported for S. aurata, concerning the observed relaxing influence-due to its brain neurotransmitters action-of the transmission of Mozart music (compared to R and B), which resulted in the achievement of maximum growth rate, body weight and improved FCR. This conclusion definitely supports the musical "understanding" and sensitivity of S. aurata to music stimuli as well as suggesting a specific effect of white noise.

title: Gilthead seabream (Sparus aurata) response to three music stimuli (Mozart-"Eine Kleine Nachtmusik," Anonymous-"Romanza," XXXX -"Violin Concerto No. 1") and white noise under recirculating water conditions.

entities_list: @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine']

entities_list: @entity1718 :: ('MESH:D005227', 'Chemical') :: ['fatty acids']

answer: @entity25781 :: (11332,Gene) :: ['Bach']


abstract: We retrospectively reviewed 46 @entity1 with superior @entity4264 during the period 1986-1992. The common symptoms included congestion of collateral veins of the neck, anterior chest wall, face, eyelids and right arm. Dyspoea and @entity848 occurred less frequently. In all but two @entity1 a histological diagnosis was made by invasive and non-invasive examination without complications. In 82% of all @entity1 a primary @entity2 was the cause of the superior @entity4264 . For 39 @entity1 radiotherapy was the first treatment of choice. To relieve the distressing symptoms @entity1 received one of two regimens employing hypofractionated radiotherapy. In regimen 3F, 25 @entity1 received three weekly high dose fractions of 8 Gy delivering a total dose of 24 Gy. Regimen 2F, applied to seven @entity1 , consisted of two weekly fractions of 8 Gy, giving a total of 24 Gy. In both regimens a good palliative result was established, however the results of the 3F regimen were superior. Using the 3F regimen a partial response was obtained in 96% of all @entity1 , and 56% achieved a complete response. With the 2F regimen a partial response was achieved in 70% of all @entity1 , and a complete response in only 28%. Minimal side effects were noted. After reviewing our experience, the 3F regimen is recommended for rapid and effective relief of the superior @entity4264 .

title: Hypofractionated radiation therapy in the treatment of superior XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity4264 :: ('MESH:D013479', 'Disease') :: ['vena cava syndrome']

entities_list: @entity848 :: ('MESH:D003490', 'Disease') :: ['cyanosis']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung carcinoma']

answer: @entity4264 :: (MESH:D013479,Disease) :: ['vena cava syndrome']


abstract: UNASSIGNED: Patch mosaic burning, in which fire is used to produce a mosaic of habitat patches representative of a range of fire histories ('pyrodiversity'), has been widely advocated to promote greater biodiversity. However, the details of desired fire mosaics for prescribed burning programs are often unspecified. Threatened small to medium-sized mammals (35 g to 5.5 kg) in the fire-prone tropical savannas of Australia appear to be particularly fire-sensitive. Consequently, a clear understanding of which properties of fire mosaics are most instrumental in influencing savanna @entity1 populations is critical. Here we use @entity1 capture data, remotely sensed fire information (i.e. time since last fire, fire frequency, frequency of late dry season fires, diversity of post-fire ages in 3 km radius, and spatial extent of recently burnt, intermediate and long unburnt habitat) and structural habitat attributes (including an index of @entity291 disturbance) to examine which characteristics of fire mosaics most influence mammals in the north-west Kimberley. We used general linear models to examine the relationship between fire mosaic and habitat attributes on total @entity1 abundance and richness, and the abundance of the most commonly detected species. Strong negative associations of @entity1 abundance and richness with frequency of late dry season fires, the spatial extent of recently burnt habitat (post-fire age <1 year within 3 km radius) and level of @entity291 disturbance were observed. Shrub cover was positively related to both @entity1 abundance and richness, and availability of rock crevices, ground @entity47 cover and spatial extent of >= 4 years unburnt habitat were all positively associated with at least some of the @entity1 species modelled. We found little support for diversity of post-fire age classes in the models. Our results indicate that both a high frequency of intense late dry season fires and extensive, recently burnt @entity47 are likely to be detrimental to mammals in the north Kimberley. A managed fire mosaic that reduces large scale and intense fires, including the retention of >= 4 years unburnt patches, will clearly benefit savanna mammals. We also highlighted the importance of fire mosaics that retain sufficient shelter for mammals. Along with fire, it is clear that grazing by introduced herbivores also needs to be reduced so that habitat quality is maintained.

title: Influence of Fire Mosaics, Habitat Characteristics and XXXX Disturbance on Mammals in Fire-Prone Savanna Landscapes of the Northern Kimberley.

entities_list: @entity47 :: ('MESH:D018458', 'Disease') :: ['vegetation']

answer: @entity291 :: (9913,Species) :: ['Cattle']


abstract: BACKGROUND _ AIMS: @entity560 , best known to regulate bone mineralization, has numerous additional roles including regulation inflammatory pathways. Recently, an increased incidence of @entity14951 ( @entity14282 ) deficiency has been found in subjects suffering from @entity409 . We here investigated if low @entity560 levels might be associated with prognosis, @entity32 and @entity166 in @entity1 with @entity82 . METHODS: We performed a prospective cohort study investigating the relation between @entity14282 levels and stages of @entity82 , mortality and complications of @entity82 , including infections. RESULTS: 251 @entity1 with @entity82 were enrolled into the present prospective cohort study. @entity14282 levels were quantified by radioimmunoassay from serum samples obtained at study inclusion. The mean follow-up time was 411    397 days with a range of 1-1382 days. 30 (12.0%) @entity1 underwent liver transplantation and 85 (33.8%) individuals died within the study. The mean serum @entity14282 concentration was 8.93    7.1 ng/ml with a range of 1.0 to 46.0 ng/ml. @entity14282 levels differed significantly between @entity1 Pugh scores and showed a negative correlation with the @entity3851 ( @entity3851 ) score. @entity1 with decompensated @entity82 and @entity166 , had significantly lower @entity14282 levels compared to subjects without complications. Low @entity14282 was associated with mortality in uni- as well as multivariate Cox regression models. CONCLUSIONS: @entity14282 deficiency is associated with advanced @entity409 and low @entity14282 levels are an indicator for a poor outcome and are associated with @entity166 .

title: Low 25-Hydroxyvitamin D Levels Are Associated with Infections and Mortality in @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Child', 'Patients', 'patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver diseases', 'liver disease']

entities_list: @entity3851 :: ('MESH:D058625', 'Disease') :: ['MELD', 'model of end stage liver disease']

entities_list: @entity166 :: ('MESH:D003141', 'Disease') :: ['infectious complications']

entities_list: @entity14951 :: ('MESH:D002112', 'Chemical') :: ['25-hydroxyvitamin D3']

entities_list: @entity560 :: ('MESH:D014807', 'Chemical') :: ['vitamin D', 'Vitamin D']

answer: @entity82 :: (MESH:D005355,Disease) :: ['Cirrhosis']


abstract: BACKGROUND _ AIMS: @entity560 , best known to regulate bone mineralization, has numerous additional roles including regulation inflammatory pathways. Recently, an increased incidence of @entity14951 ( @entity14282 ) deficiency has been found in subjects suffering from @entity409 . We here investigated if low @entity560 levels might be associated with prognosis, @entity32 and @entity166 in @entity1 with @entity82 . METHODS: We performed a prospective cohort study investigating the relation between @entity14282 levels and stages of @entity82 , mortality and complications of @entity82 , including infections. RESULTS: 251 @entity1 with @entity82 were enrolled into the present prospective cohort study. @entity14282 levels were quantified by radioimmunoassay from serum samples obtained at study inclusion. The mean follow-up time was 411    397 days with a range of 1-1382 days. 30 (12.0%) @entity1 underwent liver transplantation and 85 (33.8%) individuals died within the study. The mean serum @entity14282 concentration was 8.93    7.1 ng/ml with a range of 1.0 to 46.0 ng/ml. @entity14282 levels differed significantly between @entity1 Pugh scores and showed a negative correlation with the @entity3851 ( @entity3851 ) score. @entity1 with decompensated @entity82 and @entity166 , had significantly lower @entity14282 levels compared to subjects without complications. Low @entity14282 was associated with mortality in uni- as well as multivariate Cox regression models. CONCLUSIONS: @entity14282 deficiency is associated with advanced @entity409 and low @entity14282 levels are an indicator for a poor outcome and are associated with @entity166 .

title: Low 25-Hydroxyvitamin D Levels Are Associated with Infections and Mortality in XXXX with @entity82 .

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: AIM: In recent years, several studies with large sample sizes and recent follow-up data have been published comparing outcomes between laparoscopic Nissen fundoplication and laparoscopic Toupet fundoplication. It is now timely to be re-evaluated and synthesized long-term efficacy and adverse events of both total and partial posterior fundoplication. MATERIALS AND METHODS: Electronic searches for RCTs comparing the outcome after laparoscopic Nissen fundoplication and laparoscopic Toupet fundoplication were performed in the databases of MEDLINE, EMBASE, and the Cochrane Center Register of Controlled Trials. The data of evaluation in positive and adverse results of laparoscopic Nissen fundoplication and laparoscopic Nissen fundoplication were extracted and compared using meta-analysis. RESULTS: 13 RCTs were ultimately identified involving 814 (52.05%) and 750 (47.95%) @entity1 who underwent laparoscopic Nissen fundoplication and laparoscopic Toupet fundoplication, respectively. The operative time, perioperative complications, @entity86 , recurrence, and the rates of medication adoption or re-operation due to recurrence were not significantly different between two groups. The two types of fundoplication both reinforced the anti-reflux barrier and elevated the lower esophageal sphincter pressure. However, rates of adverse results involving @entity2026 , @entity11035 , inability to belch and re-operation due to severe @entity2026 were significantly higher after LNF. In the subgroup analysis of wrap length <=2cm, laparoscopic Nissen fundoplication was associated with a significantly higher incidence of @entity86 . However, in the subgroup wrap length>2cm, the difference was not statistically significant. CONCLUSION: Laparoscopic Toupet fundoplication might be the better surgery approach for @entity354 with a lower rate of postoperative adverse results and equal effectiveness as Laparoscopic Nissen fundoplication.

title: A Meta-Analysis of Randomized Controlled Trials to Compare Long-Term Outcomes of Nissen and Toupet Fundoplication for XXXX .

entities_list: @entity11035 :: ('MESH:C535647', 'Disease') :: ['gas-bloat syndrome']

entities_list: @entity2026 :: ('MESH:D001037', 'Disease') :: ['dysphasia']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative dysphagia', 'postoperative satisfaction']

entities_list: @entity354 :: ('MESH:D005764', 'Disease') :: ['gastroesophageal reflux disease']

answer: @entity354 :: (MESH:D005764,Disease) :: ['Gastroesophageal Reflux Disease']


abstract: UNASSIGNED: @entity1 skin colour, ie @entity2118 , differs widely among individuals, as do their responses to various types of ultraviolet radiation (UV) and their risks of @entity1489 . In some individuals, UV-induced @entity2118 persists for months to years in a phenomenon termed long-lasting @entity2118 (LLP). It is unclear whether LLP is an indicator of potential risk for @entity1489 . LLP seems to have similar features to other forms of @entity2117 , eg solar lentigines or age spots, which are clinical markers of photodamage and risk factors for @entity1613 . To investigate what UV-induced molecular changes may persist in individuals with LLP, clinical specimens from non-sunburn-inducing repeated UV exposures (UVA, UVB or UVA + UVB) at 4 months post-exposure (short-term LLP) were evaluated by microarray analysis and dataset mining. Validated targets were further evaluated in clinical specimens from six healthy individuals (three LLP+ and three LLP-) followed for more than 9 months (long-term LLP) who initially received a single sunburn-inducing UVA + UVB exposure. The results support a UV-induced @entity2117 model in which basal keratinocytes have an impaired ability to remove melanin that leads to a compensatory mechanism by neighbouring keratinocytes with increased proliferative capacity to maintain skin homeostasis. The attenuated expression of @entity34980 and other hemidesmosomal components ( @entity16246 ) leads to increased melanosome uptake by keratinocytes and points to a spatial regulation within the epidermis. The reduced density of hemidesmosomes provides supporting evidence for plasticity at the epidermal-dermal junction. Altered hemidesmosome plasticity, and the sustained nature of LLP, may be mediated by the role of @entity34980 in basal keratinocytes. The long-term sustained subtle changes detected are modest, but sufficient to create dramatic visual differences in skin colour. These results suggest that the @entity2117 phenomenon leading to increased interdigitation develops in order to maintain normal skin homeostasis in individuals with LLP. Copyright    2014 Pathological Society of Great Britain and Ireland. Published by John Wiley _ Sons, Ltd.

title: UV exposure modulates hemidesmosome plasticity, contributing to long-term XXXX in @entity1 skin.

entities_list: @entity1489 :: ('MESH:D012878', 'Disease') :: ['skin cancer']

entities_list: @entity2117 :: ('MESH:D017495', 'Disease') :: ['hyperpigmentation']

entities_list: @entity16246 :: ('5339', 'Gene') :: ['integrin a6b4 and plectin']

entities_list: @entity2118 :: ('MESH:D010859', 'Disease') :: ['pigmentation']

entities_list: @entity1613 :: ('MESH:D011230', 'Disease') :: ['precancerous lesions']

answer: @entity2118 :: (MESH:D010859,Disease) :: ['pigmentation']


abstract: UNASSIGNED: @entity1 skin colour, ie @entity2118 , differs widely among individuals, as do their responses to various types of ultraviolet radiation (UV) and their risks of @entity1489 . In some individuals, UV-induced @entity2118 persists for months to years in a phenomenon termed long-lasting @entity2118 (LLP). It is unclear whether LLP is an indicator of potential risk for @entity1489 . LLP seems to have similar features to other forms of @entity2117 , eg solar lentigines or age spots, which are clinical markers of photodamage and risk factors for @entity1613 . To investigate what UV-induced molecular changes may persist in individuals with LLP, clinical specimens from non-sunburn-inducing repeated UV exposures (UVA, UVB or UVA + UVB) at 4 months post-exposure (short-term LLP) were evaluated by microarray analysis and dataset mining. Validated targets were further evaluated in clinical specimens from six healthy individuals (three LLP+ and three LLP-) followed for more than 9 months (long-term LLP) who initially received a single sunburn-inducing UVA + UVB exposure. The results support a UV-induced @entity2117 model in which basal keratinocytes have an impaired ability to remove melanin that leads to a compensatory mechanism by neighbouring keratinocytes with increased proliferative capacity to maintain skin homeostasis. The attenuated expression of @entity34980 and other hemidesmosomal components ( @entity16246 ) leads to increased melanosome uptake by keratinocytes and points to a spatial regulation within the epidermis. The reduced density of hemidesmosomes provides supporting evidence for plasticity at the epidermal-dermal junction. Altered hemidesmosome plasticity, and the sustained nature of LLP, may be mediated by the role of @entity34980 in basal keratinocytes. The long-term sustained subtle changes detected are modest, but sufficient to create dramatic visual differences in skin colour. These results suggest that the @entity2117 phenomenon leading to increased interdigitation develops in order to maintain normal skin homeostasis in individuals with LLP. Copyright    2014 Pathological Society of Great Britain and Ireland. Published by John Wiley _ Sons, Ltd.

title: UV exposure modulates hemidesmosome plasticity, contributing to long-term @entity2118 in XXXX skin.

answer: @entity1 :: (9606,Species) :: ['human']


abstract: This study describes the expression characteristics of @entity4105 molecules using immunogold histochemical techniques on cultured @entity1 umbilical vein endothelial cells (HUVEC). The expression of @entity4105 was induced by @entity5 @entity39 factor-alpha ( @entity310 , 300 U/ml), @entity4621 ( @entity4515 , 10 ng/ml) and bacterial lipopolysaccharide (LPS, 4 micrograms/ml). No expression was demonstrated on control cells. Using the @entity575 -enhanced colloidal gold-labelling technique, at the light microscopical level, HUVEC could be distinctively subdivided into three staining types. The cell labelling index, expressed as the number of 'positively' stained cells as a proportion of all viewed cells was the highest in the LPS group. For @entity1579 ( @entity1579 ) the preembedding immunocytochemical staining method and embedding in @entity990 resin (Agar 100) according to standard procedures was used. In @entity1579 gold particles were localized in close association with the apical plasma membrane, as well as on the surface of microvillus-like projections (the latter by @entity310 group). For high resolution scanning electron microscopy (HR-SEM) the secondary (SEI) and the backscattered electron imaging (BEI) modes were used. Gold particles were randomly distributed over the whole cell surface, although they appeared to be denser in the perinuclear zone. The quantitative evaluation on SE and BE viewing (the number of gold particles per cell area in microns 2) demonstrated the highest density of labelling in the LPS-treated group, but there was only a significant difference between LPS and @entity310 groups (P < 0.01, t-test). Furthermore, the ultrastructural studies indicated that treatment with substances which up-regulate @entity4105 expression was not related to toxic cell damage or significant alterations of cellular ultrastructure.

title: Application of immunogold labelling for light and electron microscopic localization of XXXX ( @entity4105 ) on cultured @entity1 endothelial cells.

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity1579 :: ('MESH:D017096', 'Disease') :: ['transmission electron microscopy', 'TEM']

entities_list: @entity4621 :: ('CHEBI:37532', 'Chemical') :: ['phorbol ester']

answer: @entity4105 :: (6401,Gene) :: ['endothelial leukocyte adhesion molecule 1']


abstract: This study describes the expression characteristics of @entity4105 molecules using immunogold histochemical techniques on cultured @entity1 umbilical vein endothelial cells (HUVEC). The expression of @entity4105 was induced by @entity5 @entity39 factor-alpha ( @entity310 , 300 U/ml), @entity4621 ( @entity4515 , 10 ng/ml) and bacterial lipopolysaccharide (LPS, 4 micrograms/ml). No expression was demonstrated on control cells. Using the @entity575 -enhanced colloidal gold-labelling technique, at the light microscopical level, HUVEC could be distinctively subdivided into three staining types. The cell labelling index, expressed as the number of 'positively' stained cells as a proportion of all viewed cells was the highest in the LPS group. For @entity1579 ( @entity1579 ) the preembedding immunocytochemical staining method and embedding in @entity990 resin (Agar 100) according to standard procedures was used. In @entity1579 gold particles were localized in close association with the apical plasma membrane, as well as on the surface of microvillus-like projections (the latter by @entity310 group). For high resolution scanning electron microscopy (HR-SEM) the secondary (SEI) and the backscattered electron imaging (BEI) modes were used. Gold particles were randomly distributed over the whole cell surface, although they appeared to be denser in the perinuclear zone. The quantitative evaluation on SE and BE viewing (the number of gold particles per cell area in microns 2) demonstrated the highest density of labelling in the LPS-treated group, but there was only a significant difference between LPS and @entity310 groups (P < 0.01, t-test). Furthermore, the ultrastructural studies indicated that treatment with substances which up-regulate @entity4105 expression was not related to toxic cell damage or significant alterations of cellular ultrastructure.

title: Application of immunogold labelling for light and electron microscopic localization of @entity4105 ( XXXX ) on cultured @entity1 endothelial cells.

answer: @entity4105 :: (6401,Gene) :: ['ELAM-1']


abstract: This study describes the expression characteristics of @entity4105 molecules using immunogold histochemical techniques on cultured @entity1 umbilical vein endothelial cells (HUVEC). The expression of @entity4105 was induced by @entity5 @entity39 factor-alpha ( @entity310 , 300 U/ml), @entity4621 ( @entity4515 , 10 ng/ml) and bacterial lipopolysaccharide (LPS, 4 micrograms/ml). No expression was demonstrated on control cells. Using the @entity575 -enhanced colloidal gold-labelling technique, at the light microscopical level, HUVEC could be distinctively subdivided into three staining types. The cell labelling index, expressed as the number of 'positively' stained cells as a proportion of all viewed cells was the highest in the LPS group. For @entity1579 ( @entity1579 ) the preembedding immunocytochemical staining method and embedding in @entity990 resin (Agar 100) according to standard procedures was used. In @entity1579 gold particles were localized in close association with the apical plasma membrane, as well as on the surface of microvillus-like projections (the latter by @entity310 group). For high resolution scanning electron microscopy (HR-SEM) the secondary (SEI) and the backscattered electron imaging (BEI) modes were used. Gold particles were randomly distributed over the whole cell surface, although they appeared to be denser in the perinuclear zone. The quantitative evaluation on SE and BE viewing (the number of gold particles per cell area in microns 2) demonstrated the highest density of labelling in the LPS-treated group, but there was only a significant difference between LPS and @entity310 groups (P < 0.01, t-test). Furthermore, the ultrastructural studies indicated that treatment with substances which up-regulate @entity4105 expression was not related to toxic cell damage or significant alterations of cellular ultrastructure.

title: Application of immunogold labelling for light and electron microscopic localization of @entity4105 ( @entity4105 ) on cultured XXXX endothelial cells.

answer: @entity1 :: (9606,Species) :: ['human']


abstract: OBJECTIVE: The aim of this study was to clarify how extracorporeal membrane oxygenation (ECMO) is used to treatcongenital @entity2914 ( @entity7195 ) in Japan. METHODS: We completed a nationwide survey of @entity7195 involving 614 @entity1 . The subjects of this study included 43 @entity1 who underwent ECMO. We compared the clinical data ofthe @entity1 who did and did not survive for more than 90 days, and analyzed the 24-hour blood gas data in isolated @entity7195 cases in both groups. RESULTS: Of the 43 @entity7195 @entity1 , non-isolated @entity7195 that was associated with other life-threatening or @entity2008 was diagnosed in six @entity1 .Only one of these 6 @entity1 was able to discontinue ECMO and survived, and the other 5 died shortly after birth. The other 37 cases all had isolated @entity7195 . The reason for initiating ECMO in 31 of these cases was persistent pulmonary @entity101 of the newborn (PPHN). In the 37 cases with isolated @entity7195 , ECMO was initiated within 24 hours after birth. Sixteen @entity1 (37%) survived for more than 90 days, and intact discharge was possiblein eight cases. Among the isolated @entity7195 @entity1 , the 90-day survival cutoff value based onthe ROC analysis @entity894 ( @entity6926 )was 15. CONCLUSIONS: ECMO is used to treat PPHN starting from an early period after birth. However, the mortality and morbidity are not favorable. The index used to predict @entity1 who will survive following ECMO shows the lowest @entity6926 of 15.

title: Extracorporeal membrane oxygenation for XXXX in Japan.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'infants']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity894 :: ('MESH:C566784', 'Disease') :: ['of the lowestoxygenation index']

entities_list: @entity2914 :: ('MESH:D065630', 'Disease') :: ['diaphragmatic hernia']

entities_list: @entity2008 :: ('MESH:D002869', 'Disease') :: ['chromosomal anomalies']

answer: @entity2914 :: (MESH:D065630,Disease) :: ['congenital diaphragmatic hernia']


abstract: BACKGROUND: Non-specific @entity1643 (NSLBP) is a large and costly problem. It has a lifetime prevalence of 80% and results in high levels of healthcare cost. It is a major cause for long term sickness amongst the workforce and is associated with high levels of fear avoidance and kinesiophobia. Stabilisation (or 'core stability') exercises have been suggested to reduce symptoms of @entity158 and disability and form an effective treatment. Despite it being the most commonly used form of physiotherapy treatment within the UK there is a lack of positive evidence to support its use. The aims of this systematic review update is to investigate the effectiveness of stabilisation exercises for the treatment of NSLBP, and compare any effectiveness to other forms of exercise. METHODS: A systematic review published in 2008 was updated with a search of PubMed, CINAHL, AMED, Pedro and The Cochrane Library, October 2006 to October 2013. Two authors independently selected studies, and two authors independently extracted the data. Methodological quality was evaluated using the PEDro scale. Meta-analysis was carried out when appropriate. RESULTS: 29 studies were included: 22 studies (n   =   2,258) provided post treatment effect on @entity158 and 24 studies (n   =   2,359) provided post treatment effect on disability. @entity158 and disability scores were transformed to a 0 to 100 scale. Meta-analysis showed significant benefit for stabilisation exercises versus any alternative treatment or control for long term @entity158 and disability with mean difference of -6.39 (95% CI -10.14 to -2.65) and -3.92 (95% CI -7.25 to -0.59) respectively. The difference between groups was clinically insignificant. When compared with alternative forms of exercise, there was no statistical or clinically significant difference. Mean difference for @entity158 was -3.06 (95% CI -6.74 to 0.63) and disability -1.89 (95% CI -5.10 to 1.33). CONCLUSION: There is strong evidence stabilisation exercises are not more effective than any other form of active exercise in the long term. The low levels of heterogeneity and large number of high methodological quality of available studies, at long term follow-up, strengthen our current findings, and further research is unlikely to considerably alter this conclusion.

title: An update of stabilisation exercises for XXXX : a systematic review with meta-analysis.

entities_list: @entity1643 :: ('MESH:D017116', 'Disease') :: ['low back pain']

answer: @entity1643 :: (MESH:D017116,Disease) :: ['low back pain']


abstract: OBJECTIVES: To determine the efficacy and safety of the UroLume endoprosthesis as a treatment for obstructive @entity1067 in healthy @entity1 . METHODS: One hundred twenty-six @entity1 were enrolled prospectively in a multicenter North American Clinical Trial. Ninety-five @entity1 (mean age 68 +/- 7 years) had moderate or severe prostatism, whereas 31 @entity1 (mean age 76 +/- 8 years) were in urinary retention. Voiding function for all @entity1 was assessed prior to stent placement and in follow-up at 1, 3, 6, 12, and 24 months with the Madsen-Iversen symptom questionnaire, peak urinary flow rate, postvoid residual urine volume, and cystoscopic examination. RESULTS: For the nonretention cohort at 24-month follow-up, the results were as follows: (1) total symptom score decreased from 14.3 +/- 0.5 preinsertion to 5.4 +/- 0.5 (p < 0.001); (2) peak urinary flow rate increased from 9.1 +/- 0.5 mL/s preinsertion to 13.1 +/- 0.7 mL/s (p < 0.001); and (3) postvoid residual urine volume decreased from 85 +/- 9 mL to 47 +/- 8 mL (p = 0.02). For the retention group, the total symptom score, peak urinary flow rate, and postvoid residual urine volume at 24 months were 4.1 +/- 0.5, 11.4 +/- 1.0 mL/s and 46 +/- 7 mL, respectively. By 12-month follow-up, most endoprostheses were completely covered with urothelium. Although significant long-term complications were minimal, 17 endoprostheses have been explanted for an overall removal rate of 13%. All devices were removed transurethrally without subsequent sequelae to the external urinary sphincter or urethra. CONCLUSIONS: The long-term results from this North American Clinical Trial suggest that the UroLume endoprosthesis can be an effective and safe treatment for properly selected healthy @entity1 with obstructive @entity1067 . Randomized clinical trials comparing this minimally invasive procedure with transurethral resection of the prostate are now underway to document further its efficacy and safety.

title: The North American experience with the UroLume endoprosthesis as a treatment for XXXX : long-term results. The North American UroLume Study Group.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'men']

entities_list: @entity1067 :: ('MESH:D011470', 'Disease') :: ['benign prostatic hyperplasia']

answer: @entity1067 :: (MESH:D011470,Disease) :: ['benign prostatic hyperplasia']


abstract: BACKGROUND: A prospective study was conducted to assess the efficacy and @entity137 of a salvage regimen consisting of CCNU, Melphalan, and @entity2879 ( @entity3895 ) given at 28-day intervals in @entity1 with @entity978 ( @entity978 ) relapsing after primary therapy or refractory to the alternating MOPP/ABVD regimen. @entity1 AND METHODS: This study included 58 @entity1 (median age: 34 years), with resistant or relapsing @entity978 . Primary therapy had consisted of alternating MOPP/ABVD (81%) or MOPP alone (19%); 38% of @entity1 were relapsing from prior complete remission (CR) while 62% had resistant disease. @entity66 was present in 55% and B-symptoms in 72% of @entity1 ; one-fifth had bulky disease and/or bone marrow involvement. The @entity3895 was used as first salvage in half of the @entity1 . RESULTS: Complete remission was obtained in 17 @entity1 (29%); unfavorable factors for CR in univariate analysis were the presence of bulky disease and the failure to achieve CR with prior therapy. Nine @entity1 (53% of remitters) have subsequently relapsed with a 10-month median duration of CR. The 3-year overall survival after @entity3895 was 25% with an 18-month median survival; significant differences in survival were found according to the extent of disease, the presence of B-symptoms and the @entity978 status (prior sensitive or resistant disease, first or subsequent relapse). Seven @entity1 are long-term remitters (12%), and one of them has been given high-dose chemotherapy and autologous bone marrow transplantation at relapse after @entity3895 . The @entity3895 @entity137 was mostly hematological; severe @entity3043 occurred in six cases with two cases of @entity281 and one of fatal @entity548 . CONCLUSION: @entity3895 therapy was moderately effective as third-line salvage in @entity1 with @entity978 resistant to alternating MOPP/ABVD or previously given two different regimens for relapse; the @entity137 was mostly hematological and supportive therapy was needed in one-third of the @entity1 .

title: Results of @entity3895 regimen (CCNU, melphalan, and @entity2879 ) as third-line salvage therapy for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['Extranodal disease']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['fatal infections']

entities_list: @entity978 :: ('MESH:D006689', 'Disease') :: ['HD', "Hodgkin's disease"]

entities_list: @entity3043 :: ('MESH:D010198', 'Disease') :: ['pancytopenia']

answer: @entity978 :: (MESH:D006689,Disease) :: ['Hodgkin's disease']


abstract: BACKGROUND: A prospective study was conducted to assess the efficacy and @entity137 of a salvage regimen consisting of CCNU, Melphalan, and @entity2879 ( @entity3895 ) given at 28-day intervals in @entity1 with @entity978 ( @entity978 ) relapsing after primary therapy or refractory to the alternating MOPP/ABVD regimen. @entity1 AND METHODS: This study included 58 @entity1 (median age: 34 years), with resistant or relapsing @entity978 . Primary therapy had consisted of alternating MOPP/ABVD (81%) or MOPP alone (19%); 38% of @entity1 were relapsing from prior complete remission (CR) while 62% had resistant disease. @entity66 was present in 55% and B-symptoms in 72% of @entity1 ; one-fifth had bulky disease and/or bone marrow involvement. The @entity3895 was used as first salvage in half of the @entity1 . RESULTS: Complete remission was obtained in 17 @entity1 (29%); unfavorable factors for CR in univariate analysis were the presence of bulky disease and the failure to achieve CR with prior therapy. Nine @entity1 (53% of remitters) have subsequently relapsed with a 10-month median duration of CR. The 3-year overall survival after @entity3895 was 25% with an 18-month median survival; significant differences in survival were found according to the extent of disease, the presence of B-symptoms and the @entity978 status (prior sensitive or resistant disease, first or subsequent relapse). Seven @entity1 are long-term remitters (12%), and one of them has been given high-dose chemotherapy and autologous bone marrow transplantation at relapse after @entity3895 . The @entity3895 @entity137 was mostly hematological; severe @entity3043 occurred in six cases with two cases of @entity281 and one of fatal @entity548 . CONCLUSION: @entity3895 therapy was moderately effective as third-line salvage in @entity1 with @entity978 resistant to alternating MOPP/ABVD or previously given two different regimens for relapse; the @entity137 was mostly hematological and supportive therapy was needed in one-third of the @entity1 .

title: Results of XXXX regimen (CCNU, melphalan, and @entity2879 ) as third-line salvage therapy for @entity978 .

answer: @entity3895 :: (10537,Species) :: ['CAV']


abstract: BACKGROUND: A prospective study was conducted to assess the efficacy and @entity137 of a salvage regimen consisting of CCNU, Melphalan, and @entity2879 ( @entity3895 ) given at 28-day intervals in @entity1 with @entity978 ( @entity978 ) relapsing after primary therapy or refractory to the alternating MOPP/ABVD regimen. @entity1 AND METHODS: This study included 58 @entity1 (median age: 34 years), with resistant or relapsing @entity978 . Primary therapy had consisted of alternating MOPP/ABVD (81%) or MOPP alone (19%); 38% of @entity1 were relapsing from prior complete remission (CR) while 62% had resistant disease. @entity66 was present in 55% and B-symptoms in 72% of @entity1 ; one-fifth had bulky disease and/or bone marrow involvement. The @entity3895 was used as first salvage in half of the @entity1 . RESULTS: Complete remission was obtained in 17 @entity1 (29%); unfavorable factors for CR in univariate analysis were the presence of bulky disease and the failure to achieve CR with prior therapy. Nine @entity1 (53% of remitters) have subsequently relapsed with a 10-month median duration of CR. The 3-year overall survival after @entity3895 was 25% with an 18-month median survival; significant differences in survival were found according to the extent of disease, the presence of B-symptoms and the @entity978 status (prior sensitive or resistant disease, first or subsequent relapse). Seven @entity1 are long-term remitters (12%), and one of them has been given high-dose chemotherapy and autologous bone marrow transplantation at relapse after @entity3895 . The @entity3895 @entity137 was mostly hematological; severe @entity3043 occurred in six cases with two cases of @entity281 and one of fatal @entity548 . CONCLUSION: @entity3895 therapy was moderately effective as third-line salvage in @entity1 with @entity978 resistant to alternating MOPP/ABVD or previously given two different regimens for relapse; the @entity137 was mostly hematological and supportive therapy was needed in one-third of the @entity1 .

title: Results of @entity3895 regimen (CCNU, melphalan, and XXXX ) as third-line salvage therapy for @entity978 .

answer: @entity2879 :: (MESH:D005047,Chemical) :: ['VP-16']


abstract: UNASSIGNED: Accurate force field parameters for ions are essential for meaningful simulation studies of proteins and nucleic acids. Currently accepted models of ions, especially for divalent ions, do not necessarily reproduce the right physiological behavior of @entity141 and @entity1025 ions. Saxena and Sept (J. Chem. Theor. Comput. 2013, 9, 3538-3542) described a model, called the multisite-ion model, where instead of treating the ions as an isolated sphere, the charge was split into multiple sites with partial charge. This model provided accurate inner shell coordination of the ion with biomolecules and predicted better free energies for proteins and nucleic acids. Here, we expand and refine the multisite model to describe the behavior of divalent ions in concentrated @entity8723 and @entity3282 electrolyte solutions, eliminating the unusual ion-ion pairing and clustering of ions which occurred in the original model. We calibrate and improve the parameters of the multisite model by matching the osmotic pressure of concentrated solutions of @entity8723 to the experimental values and then use these parameters to test the behavior of @entity3282 solutions. We find that the concentrated solutions of both divalent ions exhibit the experimentally observed behavior with correct osmotic pressure, the presence of solvent separated ion pairs instead of direct ion pairs, and no aggregation of ions. The improved multisite model for ( @entity1025 and @entity141 ) can be used in classical simulations of biomolecules at physiologically relevant salt concentrations.

title: Multisite Ion Model in Concentrated Solutions of Divalent Cations ( @entity8723 and XXXX ): Osmotic Pressure Calculations.

answer: @entity3282 :: (CHEBI:3312,Chemical) :: ['CaCl2']


abstract: UNASSIGNED: Accurate force field parameters for ions are essential for meaningful simulation studies of proteins and nucleic acids. Currently accepted models of ions, especially for divalent ions, do not necessarily reproduce the right physiological behavior of @entity141 and @entity1025 ions. Saxena and Sept (J. Chem. Theor. Comput. 2013, 9, 3538-3542) described a model, called the multisite-ion model, where instead of treating the ions as an isolated sphere, the charge was split into multiple sites with partial charge. This model provided accurate inner shell coordination of the ion with biomolecules and predicted better free energies for proteins and nucleic acids. Here, we expand and refine the multisite model to describe the behavior of divalent ions in concentrated @entity8723 and @entity3282 electrolyte solutions, eliminating the unusual ion-ion pairing and clustering of ions which occurred in the original model. We calibrate and improve the parameters of the multisite model by matching the osmotic pressure of concentrated solutions of @entity8723 to the experimental values and then use these parameters to test the behavior of @entity3282 solutions. We find that the concentrated solutions of both divalent ions exhibit the experimentally observed behavior with correct osmotic pressure, the presence of solvent separated ion pairs instead of direct ion pairs, and no aggregation of ions. The improved multisite model for ( @entity1025 and @entity141 ) can be used in classical simulations of biomolecules at physiologically relevant salt concentrations.

title: Multisite Ion Model in Concentrated Solutions of Divalent Cations ( XXXX and @entity3282 ): Osmotic Pressure Calculations.

answer: @entity8723 :: (MESH:D015636,Chemical) :: ['MgCl2']


abstract: The anti-malarial agent @entity8185 ( @entity4601 ) has strong anti-angiogenic activity. This study aimed to investigate the molecular mechanism underlying this effect of @entity4601 on angiogenesis. We found that @entity4601 shows a dose-dependent inhibition of proliferation and migration of in HUVECs. @entity4601 specifically down-regulates the mRNA and protein expression of @entity11132 in endothelial cells. Treatment with @entity4601 increases IkB-a protein and blocks nuclear translocation of NF-kB @entity1992 . In addition, @entity4601 directly regulates @entity11132 promoter activity through @entity1992 binding motif, and decreases the binding activity of @entity1992 and @entity11132 promoter, suggesting defective NF-kB signaling may underlie the observed effects of @entity4601 on @entity11132 expression. In the presence of the NF-kB inhibitor @entity17727 , @entity4601 could not further repress @entity11132 . Co-treatment with @entity17727 and @entity4601 produced minimal changes compared to the effects of either drug alone in in vitro angiogenesis assays. Similar findings were found in vivo through a @entity19 @entity2479 model examining the effects of @entity17727 and @entity4601 . Our data suggested that @entity4601 inhibits angiogenesis largely through repression of the NF-kB pathway. @entity4601 is well tolerated, and therefore may be an ideal candidate to use clinically as an angiogenesis inhibitor for @entity5 treatment.

title: @entity8185 targets XXXX via the NF-kB pathway in endothelial cells to inhibit angiogenesis.

entities_list: @entity2479 :: ('MESH:D012173', 'Disease') :: ['retinal neovascularization']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity8185 :: ('MESH:C039060', 'Chemical') :: ['dihydroartemisinin']

answer: @entity11132 :: (16542(Tax:10090),Gene) :: ['VEGFR2']


abstract: The anti-malarial agent @entity8185 ( @entity4601 ) has strong anti-angiogenic activity. This study aimed to investigate the molecular mechanism underlying this effect of @entity4601 on angiogenesis. We found that @entity4601 shows a dose-dependent inhibition of proliferation and migration of in HUVECs. @entity4601 specifically down-regulates the mRNA and protein expression of @entity11132 in endothelial cells. Treatment with @entity4601 increases IkB-a protein and blocks nuclear translocation of NF-kB @entity1992 . In addition, @entity4601 directly regulates @entity11132 promoter activity through @entity1992 binding motif, and decreases the binding activity of @entity1992 and @entity11132 promoter, suggesting defective NF-kB signaling may underlie the observed effects of @entity4601 on @entity11132 expression. In the presence of the NF-kB inhibitor @entity17727 , @entity4601 could not further repress @entity11132 . Co-treatment with @entity17727 and @entity4601 produced minimal changes compared to the effects of either drug alone in in vitro angiogenesis assays. Similar findings were found in vivo through a @entity19 @entity2479 model examining the effects of @entity17727 and @entity4601 . Our data suggested that @entity4601 inhibits angiogenesis largely through repression of the NF-kB pathway. @entity4601 is well tolerated, and therefore may be an ideal candidate to use clinically as an angiogenesis inhibitor for @entity5 treatment.

title: XXXX targets @entity11132 via the NF-kB pathway in endothelial cells to inhibit angiogenesis.

answer: @entity8185 :: (MESH:C039060,Chemical) :: ['Dihydroartemisinin']


abstract: The complexation of Cm(iii) with the recombinant N-lobe of human serum @entity69 (hTf/2N) is investigated in the pH range from 4.0 to 11.0 using TRLFS. At pH >=  7.4 a Cm(iii) hTf/2N species is formed with Cm(iii) bound at the @entity596 binding site. The results are compared with Cm(iii) @entity69 interaction at the C-lobe and indicate the similarity of the coordination environment of the C- and N-terminal binding sites with four @entity535 residues of the protein, two @entity2507 molecules and three additional ligands (e.g. synergistic anions such as @entity6445 ) in the first coordination sphere. Measurements at c( @entity6445 )tot = 0.23 mM (ambient @entity6445 concentration) and c(carbonate)tot = 25 mM (physiological @entity6445 concentration) show that an increase of the total @entity6445 concentration suppresses the formation of the Cm(iii) hTf/2N species significantly. Additionally, the three Cm(iii) carbonate species Cm(CO3)(+), Cm(CO3)2(-) and Cm(CO3)3(3-) are formed successively with increasing pH. In general, @entity6445 complexation is a competing reaction for both Cm(iii) complexation with @entity69 and hTf/2N but the effect is significantly higher for the half molecule. At c( @entity6445 )tot = 0.23 mM the complexation of Cm(iii) with @entity69 and hTf/2N starts at pH >=  7.4. At physiological @entity6445 concentration the Cm(iii) @entity69 species II forms at pH >=  7.0 whereas the Cm(iii) hTf/2N species is not formed until pH > 10.0. Hence, our results reveal significant differences in the complexation behavior of the C-terminal site of @entity69 and the recombinant N-lobe (hTf/2N) towards trivalent actinides.

title: Complexation of Cm(iii) with the recombinant N-lobe of human serum XXXX studied by time-resolved laser fluorescence spectroscopy (TRLFS).

entities_list: @entity6445 :: ('CHEBI:41609', 'Chemical') :: ['carbonate']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

answer: @entity69 :: (7018,Gene) :: ['transferrin']


abstract: The techniques introduced by Kimura and Ingram et al. were applied to assess the distribution of motor refractory periods (DMRPs) in peroneal nerve fibres of 28 diabetics with symptoms indicating @entity305 and in 28 controls. Results were compared with conventional motor nerve conduction velocity (MNCV) and compound muscle action potential (CMAP) measurements. MRP95 and MRP90 (the 5% and 10% slowest recovering fibres) obtained with Ingram's technique were prolonged in the @entity6 @entity1 . In the 26 @entity1 with a value of MRP95 and MNCV, a prolonged MRP95 and a decreased MNCV were found in 12 @entity1 . Thus conventional MNCV had a sensitivity of 46% to detect @entity16 ; addition of MRP95 obtained with Ingram's technique raised the sensitivity to 73%. Specificity was 100% in both cases. With Kimura's technique or with the fast recovering fibres in Ingram's technique, it was not possible to discriminate the @entity1 from the controls. This study indicates that measurement of the DMRP with the technique introduced by Ingram et al. improves the electrophysiological diagnosis of @entity3949 .

title: Motor nerve refractory period distribution assessed by two techniques in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy']

entities_list: @entity3949 :: ('MESH:D003929', 'Disease') :: ['diabetic polyneuropathy']

entities_list: @entity305 :: ('MESH:D011115', 'Disease') :: ['polyneuropathy']

answer: @entity3949 :: (MESH:D003929,Disease) :: ['diabetic polyneuropathy']